The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial is the first to assess cardiovascular outcomes of an SGLT-2 inhibitor in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.